Business Wire

FCC Grants LeoSat U.S. Market Access

Share

LeoSat Enterprises, the dynamic young company which is launching a unique new data network comprised of a constellation of up to 108 low-earth-orbit communications satellites, has been awarded the authority by the U.S. Federal Communications Commission (FCC) to provide NGSO (non-geostationary satellite orbit) services in the United States.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005890/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

LeoSat's Global Business Backbone in Space (Graphic: Business Wire)

The increasing demand for business connectivity and with it, the need to move large quantities of data quickly and securely around the world, is fast outpacing the infrastructure in place to carry it. Existing networks are already carrying more than 1 Zeta Byte of traffic globally and this is set to grow exponentially.

The FCC market access grant will allow LeoSat to address currently unmet demand for high-bandwidth, low-latency, high-security data transmissions from large commercial and government customers in the United States. Designed as a backbone in space for global business, LeoSat’s data network will enable new opportunities for sectors such as enterprise-to-enterprise communications, telecommunications, oil & gas operations and maritime services, delivering premise-to-premise high-speed data (greater than 1 Gbps) with unmatched security to any location in the world. Moreover, whilst LeoSat's core focus is solving essential business communications challenges, the unique design of LeoSat’s constellation means capacity will also be available to enable a new level of connectivity services for Internet and cellular backhaul for remote and underserved communities.

Using optical inter-satellite links and on-board processing and operating in polar orbits at an altitude five times closer to the Earth than medium earth orbit satellites and 25 times closer than geostationary orbit (“GSO”) satellites, the LeoSat System offers numerous advantages with respect to high throughput, low latency, and full global coverage. These advantages, in turn, will allow LeoSat to provide enterprise-grade, highly secure data transmissions with up to 1.2 Gbps of full-duplex connectivity per link (and 5.2 Gbps where needed), along with low latency of less than 20 ms. The high-throughput satellites will form a mesh network interconnected through inter-satellite laser links, creating an optical backbone that is approximately 1.5 times faster than terrestrial fiber networks.

For Enterprise and Government customers, the key attributes of the LeoSat system fulfil a critical communications need, for example, by giving banks, governments or research centers ultra-secure networks with global offices, providing significantly more bandwidth for oil & gas and mining exploration than is available today, enabling seamless connectivity for shipping & fleet management, or providing primary 4G and 5G satellite backhaul connectivity for cellular operators.

LeoSat’s CEO, Mark Rigolle said, “Getting approval from the U.S. Federal Communications Commission – among the world’s most sophisticated radio frequency regulators – is an important milestone for LeoSat and recognizes that we have a unique solution for high-speed and ultra-secure enterprise connectivity. I am delighted by this significant step forward for LeoSat as we continue to make excellent progress on our journey to deliver the world’s first business backbone in space, opening-up new markets for data networking, telecoms, enterprise and government communications across the globe”.

LeoSat was represented before the U.S. Federal Communications Commission by Wilkinson, Barker and Knauer with respect to LeoSat’s U.S. market access grant.

ENDS

About LeoSat Enterprises

LeoSat Enterprises was established to leverage the latest developments in satellite communications technologies to develop and launch a new low-earth-orbit satellite constellation which will provide the first commercially available, business grade, extremely high-speed and secure data service worldwide.

With up to 108 low-earth-orbit communications satellites in the constellation LeoSat is the first company to have all the High Throughput Satellites (HTS) in the constellation interconnected through laser links, creating an optical backbone in space which is about 1.5 times faster than terrestrial fiber backbones and without the need for any terrestrial touchpoints. This unique set of features enables LeoSat to provide instant infrastructure from anywhere to everywhere which is fast, secure and reliable.

Based in Washington DC, LeoSat is currently working with Thales Alenia Space for the low-earth-orbit constellation of Ka-band communications satellites. Once operational, the constellation will provide high-speed, low-latency and highly secure communications and bandwidth for business operations in the Enterprise, Telecoms, Energy, Maritime, Government and international business markets. Launch of the constellation is expected in 2020. www.leosat.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Melanie Dickie
VP Marketing & Communications, LeoSat Enterprises
Tel: +31 6 14 22 97 62
Email: Melanie@leosat.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

HiddenA line styled icon from Orion Icon Library.Eye